Summit Opportunity of those interested in Onli... - CLL Support

CLL Support

22,456 members38,597 posts

Summit Opportunity of those interested in Online Patient Advocacy

bkoffman profile image
bkoffmanCLL CURE Hero
0 Replies

HealtheVoices 2016 is a great idea and a super opportunity for anyone wanting to share best practices and needing to learn that we are not alone in our struggles to build an online patient community.

What is it is a summit that mixes together established online superstars and passionate health advocates and new learners in the digital domain.

What we all have in common is a passion to advocate for our fellow patients and caregivers, a willingness to share, and an openness to learning.

Last year there were folks there from the HIV and cancer and arthritis and colitis and diabetes and psychiatric worlds, all using the internet as a tool for education and support. While it is mostly young advocates, all ages are represented. I learnt so much and made many new friends.

Below is a link to a video from last year's event:

vimeo.com/149168213

If you look carefully, you might see me and catch my name in the credits.

This year the conference will be in Chicago April 15-17.

So if you share my need to help other patients on the world wide web through your blog or Twitter of Facebook or wherever, please consider applying.

The link to apply and learn more is healthevoices16.com

See you there.

Brian

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .

You may also like...

First Online Electronic Blood Test Results on Patients Know Best

electronically via the online system provided by organisation \\"Patients Know Best:...

Top 10 list of what we need to know about lymphoma

by LRF and Patient Power. Finally, if you haven’t completed our 5 minute survey on how you choose...

Your opportunity to suggest questions for Patient Power ASH 2013 Interviews

trying to interview CLL experts from around the world and in their languages. Why shouldn't we have...

ASH 2018: ECOG trial shows superiority of Ibrutinib and rituximab over FCR

free survival for frontline patients <70 years old.. For more see: https://cllsociety.org/2019/01/as

NEW DISCOVERIES WITH RICHTERS

Farber, I felt I should share it with all of you. This is sort of a Spoiler before you read the...